Mereo BioPharma Group plc (NasdaqCM: MREO)
Health Care · Biotechnology · GB
$0.29
-1.30% today · -86.2% 1Y
Mereo BioPharma Group plc (NasdaqCM: MREO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $45.90M and employs 39 people.
Over the last twelve months the share price has lost 86.2%, trading between 0.20 and 2.37.
Tweenvest scores Mereo BioPharma Group plc across four factors: quality 36/100, value 28/100. Its strongest factor is quality.
MREO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $45.90M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.18
- Dividend yield
- —
- Beta (5Y)
- 0.14
- 52-week high
- $2.37
- 52-week low
- $0.20
- Avg volume (3M)
- —
- Shares outstanding
- 159.69M
- Employees
- 39
- Next earnings
- —
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
- ISIN
- US5894921072
- Founded
- 2015
- Listed since
- Apr 24, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Solasia Pharma K.K.TSE: 4597 | $46.69M | ¥27.00 | -6.90% |
| OncoTherapy Science, Inc.TSE: 4564 | $46.54M | ¥18.00 | -5.26% |
| Apollomics, Inc.NasdaqCM: APLM | $46.34M | $21.10 | -1.86% |
| Prescient Therapeutics LimitedASX: PTX | $46.16M | AU$0.06 | -12.12% |
| ImageneBio, Inc.NasdaqCM: IMA | $45.86M | $4.04 | -4.72% |
| Harvard Apparatus Regenerative Technology Inc.OTCPK: HRGN | $45.23M | $2.23 | -3.04% |
| GenMont Biotech IncorporationTWSE: 3164 | $44.54M | NT$16.80 | -0.88% |
| Clene Inc.NasdaqCM: CLNN | $44.06M | $3.10 | -19.69% |
Figures last refreshed Oct 18, 2026.